Metabolic reprogramming by traditional Chinese medicine and its role in effective cancer therapy

Abstract

Metabolic reprogramming, characterized by alterations of cellular metabolic patterns, is fundamentally important in supporting the malignant behaviors of cancer cells. It is considered as a promising therapeutic target against cancer. Traditional Chinese medicine (TCM) and its bioactive components have been used in cancer therapy for an extended period, and they are well-known for their multi-target pharmacological functions and fewer side effects. However, the detailed and advanced mechanisms underlying the anticancer activities of TCM remain obscure. In this review, we summarized the critical processes of cancer cell metabolic reprogramming, including glycolysis, mitochondrial oxidative phosphorylation, glutaminolysis, and fatty acid biosynthesis. Moreover, we systemically reviewed the regulatory effects of TCM and its bioactive ingredients on metabolic enzymes and/or signal pathways that may impede cancer progress. A total of 46 kinds of TCMs was reported to exert antitumor effects and/or act as chemosensitizers via regulating metabolic processes of cancer cells, and multiple targets and signaling pathways were revealed to contribute to the metabolic-modulating functions of TCM. In conclusion, TCM has its advantages in ameliorating cancer cell metabolic reprogramming by its poly-pharmacological actions. This review may shed some new light on the explicit recognition of the mechanisms of anticancer actions of TCM, leading to the development of natural antitumor drugs based on reshaping cancer cell metabolism.

Keywords: Amino acid metabolism; Astragalus polysaccharide (PubChem CID: 2782115); Atractylenolide I (PubChem CID: 5321018); Berberine (PubChem CID: 2353); Brutieridin (PubChem CID: 101485561); Bufalin (PubChem CID: 9547215); Cancer cell metabolic reprogramming; Carnosic acid (PubChem CID: 65126); Celastrol (PubChem CID: 122724); Chlorogenic acid (PubChem CID: 1794427); Chrysin (PubChem CID: 5281607); DT-13 (PubChem CID: 101514160); Desmethoxycurcumin (PubChem CID: 5469424); Dioscin (PubChem CID: 119245); Emodin (PubChem CID: 3200); Euxanthone (PubChem CID: 5281631); Glycolysis; L42 (PubChem CID: 5288052); Licochalcone A (PubChem CID: 5318998); Lipid metabolism; MAP30 (PubChem CID: 451600); Matrine (PubChem CID: 91466); Melitidin (PubChem CID: 101485562); Melittin (PubChem CID: 16133648); Oleanolic acid (PubChem CID: 10494); Oridonin (PubChem CID: 5321010); Osthole (PubChem CID: 10228); Physapubescin I (PubChem CID: 132529929); Polyphyllin Ⅵ (PubChem CID: 10417550); Protopanaxadiol (PubChem CID: 9920281); Quercetin (PubChem CID: 5280343); Resibufogenin (PubChem CID: 6917974); Rhein (PubChem CID: 10168); Scutellarin (PubChem CID: 185617) Astragaloside IV (PubChem CID: 13943297); Shikonin (PubChem CID: 479503); Tanshinone IIA (PubChem CID: 164676); Tetrandrine (PubChem CID: 73708); Traditional Chinese medicine.